# Phase I/II Thymus Transplantation With Immunosuppression #950

> **NCT00579527** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sumitomo Pharma Switzerland GmbH** · enrollment: 14 (actual)

## Conditions studied

- DiGeorge Anomaly
- Complete DiGeorge Anomaly
- Complete Atypical DiGeorge Anomaly
- Complete DiGeorge Syndrome
- Complete Atypical DiGeorge Syndrome

## Interventions

- **BIOLOGICAL:** Cultured Thymus Tissue for Implantation (CTTI)
- **OTHER:** Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation
- **PROCEDURE:** Blood Draw
- **DRUG:** Rabbit anti-thymocyte globulin
- **DRUG:** Cyclosporine
- **DRUG:** Tacrolimus
- **DRUG:** Methylprednisolone or Prednisolone
- **DRUG:** Daclizumab
- **DRUG:** Mycophenolate mofetil

## Key facts

- **NCT ID:** NCT00579527
- **Lead sponsor:** Sumitomo Pharma Switzerland GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12-19
- **Primary completion:** 2011-12
- **Final completion:** 2017-12-31
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2022-03-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00579527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00579527, "Phase I/II Thymus Transplantation With Immunosuppression #950". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00579527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*